Posted on: Thursday, 13 January 2011, 08:00 CST
PRINCETON, N.J., Jan. 13, 2011 /PRNewswire/ — Novo Nordisk, a world leader in diabetes care, has launched a comprehensive, highly customizable online support program for people living with diabetes called Cornerstones4Care(TM). Through advanced information management technology, Cornerstones4Care will be a one-stop source to learn about diabetes and innovative Novo Nordisk treatment options and delivery device systems. People can also receive recipes, look up food nutritional values, connect with others and even receive daily action plans all tailored to a patient’s lifestyle and information needs.
To view the multimedia assets associated with this release, please click: multivu.prnewswire.com/mnr/novonordisk/46915/
(Photo: photos.prnewswire.com/prnh/20110113/MM06932)
Patients can log on to Cornerstones4Care.com to see if they qualify for a money-saving offer on Novo Nordisk insulin products. The program focuses on four “cornerstones” of diabetes control – checking blood sugar, eating healthy, engaging in physical activity and taking diabetes medicines. The program brings together a number of unique features in one place: diabetes and treatment information, interactive and downloadable tools, strategies for dealing with special situations. This includes things like travel, support for checking blood sugar, and innovative resources to make it easy and fun to eat healthy foods and be active.
“We wanted to provide diabetes patients with a wide range of information and support in these four key areas of diabetes management to help them achieve their personal goals,” said Camille Lee, Vice President, Diabetes Marketing. “Whether you are newly diagnosed or have been living with diabetes for a long time, everyone needs on-going support to stay engaged and on track with their diabetes care and Cornerstones4Care was developed to do that.”
For example, different healthy eating tips are offered to someone who indicates they like to cook at home versus eat out in restaurants. Unique features like the Menu Planner allow members to create their own menu of diabetes-friendly dishes, then generate a grocery list based on the options so that smart, healthy food choices can be made.
Novo Nordisk is committed to helping patients achieve their diabetes goals and saw a need to offer an improved online experience so patients can become better informed about their diabetes and what they can do to manage it. Cornerstones4Care will replace the Changing Life with Diabetes site, which will phase out over the next few months.
Novo Nordisk offers a comprehensive line of insulin analog products that include Levemir® (insulin detemir [rDNA origin] injection), NovoLog® [insulin aspart (rDNA origin) injection], and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]). A leader in diabetes care, Novo Nordisk created the first pre-filled insulin pen device called FlexPen®.
Prescribing information for Levemir®, NovoLog®, and NovoLog® Mix 70/30 are available by contacting Novo Nordisk at 1-800-727-6500 or visiting Levemir-us.com, NovoLog.com, and NovoLogMix70-30.com.
About Levemir® (insulin detemir [rDNA origin] injection)
Indications and Usage:
Levemir® is a man-made long-acting insulin that is used to control high blood sugar in adults and children with diabetes mellitus.
Important Safety Information:
Do not take Levemir® if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in Levemir®. If you take too much Levemir® your blood sugar may fall too low.
Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take Levemir®.
Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.
Never mix Levemir® with other insulin products or use in an insulin pump.
Needles and Levemir® FlexPen® must not be shared.
Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your Levemir® dose may change if you take other medicines.
The most common side effect of insulin therapy, including Levemir®, is low blood sugar (hypoglycemia). other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.
Please see levemir-us.com for Levemir® complete Prescribing Information.
About NovoLog® (insulin aspart [rDNA origin] injection)
Indications and Usage:
NovoLog® is a man-made insulin that is used to control high blood sugar in adults and children with diabetes mellitus.
Important Safety Information:
Do not take NovoLog® if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in NovoLog®.
NovoLog® is a fast-acting insulin. you should eat a meal within 5 to 10 minutes after using NovoLog® to avoid low blood sugar. Do not inject NovoLog® if you do not plan to eat right after using NovoLog®. Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take NovoLog®.
Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.
Do not mix NovoLog® with any other insulins when used in a pump or with any insulins other than NPH when used with injections by syringe.
Needles and NovoLog® FlexPen® must not be shared.
Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your NovoLog® dose may change if you take other medicines.
NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.
The most common side effect of NovoLog® is low blood sugar (hypoglycemia). other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.
Please see novolog.com for NovoLog® complete Prescribing Information.
About NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])
Indications and Usage:
NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a man-made insulin that is used to control high blood sugar in adults with diabetes mellitus.
It is not known if NovoLog® Mix 70/30 is safe or effective in children.
Important Safety Information:
Do not take NovoLog® Mix 70/30 if your blood sugar is too low (hypoglycemia) or if you are allergic to any of the ingredients in NovoLog® Mix 70/30. If you take too much NovoLog® Mix 70/30, your blood sugar may fall too low (hypoglycemia).
NovoLog® Mix 70/30 starts acting fast. If you have Type 1 diabetes, inject it up to 15 minutes before you eat a meal. If you have Type 2 diabetes, you may inject NovoLog® Mix 70/30 up to 15 minutes before or after starting your meal.
Check your blood sugar levels regularly. Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar levels. Do not make any changes to your dose or type of insulin unless your healthcare provider tells you to. Alcohol, including beer and wine, may affect your blood sugar when you take NovoLog® Mix 70/30.
Before using NovoLog® Mix 70/30, tell your health care provider about all medicines you take and all of your medical conditions, including if you have kidney or liver problems or if you are pregnant or breastfeeding. It is not known if NovoLog® Mix 70/30 will harm your unborn baby or pass into breast milk. Your NovoLog® Mix 70/30 dose may change if you take other medicines.
Do not inject NovoLog® Mix 70/30 with any other insulin products or use in an insulin pump.
Do not share needles, insulin pens or syringes with others.
The most common side effects of NovoLog® Mix 70/30 include skin thickening or pits at the injection site (lipodystrophy), weight gain, swelling of your hands and feet, and vision changes. Serious adverse events may include low blood sugar (hypoglycemia), low potassium in your blood (hypokalemia), local allergic reactions at the injection site (like redness, swelling, and itching), and whole body reactions. get medical help right away if you have any of these symptoms of an allergic reactions: a rash over the whole body, have trouble breathing, fast heart rate, sweating or if you feel faint. Ask your health care provider or pharmacist for more information.
Please see novologmix70-30.com for complete NovoLog® Mix 70/30 Prescribing Information.
Levemir® and NovoLog® are registered trademarks and Cornerstones4Care(TM) is a trademark of Novo Nordisk A/S.
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the new York Stock Exchange (NVO). for more information, visit novonordisk-us.com.
About Diabetes
In the United States one in 13, or 23.6 million people, have diabetes, a condition in which the body does not produce or properly use insulin, the hormone needed to convert sugar, starches and other food into energy needed for daily life. Poorly or untreated diabetes can lead to a long list of health complications such as heart disease, stroke, kidney disease, high blood pressure, blindness, nerve problems and amputations.
More News in this Category